Immunic Inc (IMUX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immunic Inc (IMUX) has a cash flow conversion efficiency ratio of 2.889x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.28 Million) by net assets ($-6.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See IMUX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Immunic Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Immunic Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Immunic Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunic Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Heungkuk F&M I
KO:000540
|
0.097x |
|
Userjoy Technology Co Ltd
TWO:3546
|
0.104x |
|
INFOM
KLSE:0265
|
0.045x |
|
Acme United Corporation
NYSE MKT:ACU
|
-0.019x |
|
Bharat Wire Ropes Limited
NSE:BHARATWIRE
|
0.069x |
|
Vieworks Co. Ltd
KQ:100120
|
0.043x |
|
MAX Automation SE
XETRA:MXHN
|
0.111x |
|
Silver Mountain Resources Inc
V:AGMR
|
-0.044x |
Annual Cash Flow Conversion Efficiency for Immunic Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Immunic Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see IMUX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-6.67 Million | $-85.81 Million | 12.859x | +379.56% |
| 2024-12-31 | $18.43 Million | $-84.77 Million | -4.600x | -87.88% |
| 2023-12-31 | $28.93 Million | $-70.83 Million | -2.448x | -327.23% |
| 2022-12-31 | $113.68 Million | $-65.14 Million | -0.573x | +12.49% |
| 2021-12-31 | $127.11 Million | $-83.23 Million | -0.655x | -125.41% |
| 2020-12-31 | $158.78 Million | $-46.12 Million | -0.290x | +40.61% |
| 2019-12-31 | $58.36 Million | $-28.55 Million | -0.489x | +85.92% |
| 2018-12-31 | $12.43 Million | $-43.16 Million | -3.473x | -330.30% |
| 2017-12-31 | $50.04 Million | $-40.40 Million | -0.807x | -31.88% |
| 2016-12-31 | $58.45 Million | $-35.77 Million | -0.612x | -0.88% |
| 2015-12-31 | $82.33 Million | $-49.95 Million | -0.607x | -45.00% |
| 2014-12-31 | $97.56 Million | $-40.83 Million | -0.418x | +39.50% |
| 2013-12-31 | $41.42 Million | $-28.65 Million | -0.692x | -157.11% |
| 2012-12-31 | $-7.63 Million | $-9.24 Million | 1.211x | +748.41% |
| 2011-12-31 | $-54.85 Million | $-7.83 Million | 0.143x | -- |
About Immunic Inc
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative… Read more